You are here:

busulfan, 6mg/ml, intravenous (Busilvex)

Advice

Following a full submission

busulfan for intravenous infusion (Busilvex®) is accepted for use within NHS Scotland as part of a combination regimen for conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in paediatric and adult patients. The intravenous preparation offers advantages to patients over the oral formulation in terms of convenience of administration and predictability of blood levels.

In adults it should be followed by cyclophosphamide (BuCy2) and in children it should be followed by cyclophosphamide (BuCy4) or by melphalan (BuMel).

Drug Details

Drug Name: busulfan, 6mg/ml, intravenous (Busilvex)
SMC Drug ID: 337/06
Manufacturer: Pierre Fabre Ltd
Indication: Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 15 January 2007

Back